Blogs
Explore our latest pharmaceutical and healthcare blogs for expert perspectives, strategic insights, and emerging trends across R&D, market access, digital health, and regulatory science—curated to inform, inspire, and empower your next move.
Real-world evidence is no longer optional in market access discussions.…
For many biopharma teams, Phase III is treated as the…
The Inflation Reduction Act (IRA) continues to reshape the U.S.…
The Collapse & Comeback of Digital Therapeutics: What the Industry Learned and Where It’s Going Next
For a few years, digital therapeutics were treated as inevitable.…
Cell and gene therapies are no longer a niche category.…
The quiet truth about rare disease medicines is that a…
Japan has quietly turned its HTA framework into one of…
For years, the United States and the United Kingdom have…
2025 almost felt like pharma pressed a reset button on…
With the healthcare landscape shifting rapidly, teams across biopharma, consulting,…
The U.S. healthcare system never really sits still but 2026…
In the fast‐moving world of biopharma innovation, it’s easy to…
Need customize support?
Thelansis also caters to your specific needs by providing customized reports that satisfy your organizational requirements. Get on-demand customization of the report’s scope to exactly meet your needs.